[A25-41] Garadacimab (hereditary angioedema) – Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2025
Project no.:
A25-41
Commission:
Commission awarded on 03.03.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
For routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older
Hint of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-41